7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,784.92

-118.08

-0.16%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

NYSE American - Delayed Quote USD

Oragenics, Inc. (OGEN)

0.3492 +0.0001 (+0.04%)

At close: November 6 at 3:58:41 PM EST

Loading Chart for OGEN

Chart Range Bar

Interval:

In partnership with ChartIQ

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

ORAGENICS PROVIDES INVESTOR UPDATE

ORAGENICS PROVIDES INVESTOR UPDATE

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Sidoti Events, LLC's May Micro-Cap Virtual Conference

Sidoti Events, LLC's May Micro-Cap Virtual Conference

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Mobilize your Website

View Site in Mobile | Classic

Share by: